GDTC Short Interest
CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $14.2M, listed on NASDAQ, employing roughly 43 people, carrying a beta of -0.17 to the broader market. CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. Led by Chee Kong Choo, public since 2023-04-14.
Short interest is the total number of shares currently sold short and not yet covered, reported bi-monthly by FINRA. Days to cover (short interest divided by average daily volume) indicates how long it would take short sellers to close positions, with higher values signaling greater squeeze potential.
- Settlement Date
- 2026-05-15
- Short Interest
- 71.1K
- Previous Short Interest
- 68.1K
- Change
- 4.34%
- Days to Cover
- 2.69
- Avg Daily Volume
- 26.5K
- Avg Days to Cover (24 reports)
- 4.25
Showing 24 bi-monthly FINRA short interest reports for CytoMed Therapeutics Limited.
Learn how short interest is reported and how to read the data →
Frequently asked GDTC short interest questions
- What is the current GDTC short interest?
- As of the May 15, 2026 settlement, CytoMed Therapeutics Limited (GDTC) short interest is 71.1K shares, a +4.34% change from the prior period. FINRA publishes short interest twice monthly on the 15th and last business day of each month under Rule 4560.
- What is the GDTC days-to-cover ratio?
- Days-to-cover is 2.69, calculated as short interest divided by average daily volume. It estimates how many trading days closing all short positions would consume given typical liquidity. Values above 5 days are commonly cited as elevated; values above 10 days are squeeze-relevant.
- How does GDTC short interest affect options pricing?
- High short interest changes options pricing through three mechanics: borrow-rebate effects (synthetic long stock trades below frictionless put-call parity by approximately the borrow rebate when shares are hard-to-borrow), gamma-squeeze setup risk (if dealers are short gamma against retail call buying, dealer hedge flow can amplify upward moves), and elevated event-vol pricing on names with squeeze potential. See the canonical short-interest documentation for the full mechanism.